Monoisoamyl ester of DMSA reduces 203Hg(NO3)2 retention in rats: 1. Chelation therapy during pregnancy

✍ Scribed by Maja Blanuša; Ljerka Prester; Martina Piasek; Krista Kostial; Mark M. Jones; Pramod K. Singh

• Book ID: 101299558
• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 75 KB
• Volume: 10
• Category: Article
• ISSN: 0896-548X
• DOI: 10.1002/(sici)1520-670x(1997)10:3<173::aid-jtra4>3.0.co;2-c

✦ Synopsis

In this study, efficacy of monoisoamyl meso-2,3-dimercaptosuccinate (Mi-ADMS) was tested to mobilize mercury in the period of gestation in rats. Its action was compared to meso-2,3-dimercaptosuccinic acid (DMSA). Pregnant dams (in second third of gestation) received a single intravenous injection of 203 Hg(NO 3 ) 2 and oral chelating therapy with DMSA or Mi-ADMS 0.5, 24, and 48 hours after that. Each chelator was administered in three single doses of 0.5 mmol/kg body weight on three consecutive days. The fifth day after 203 Hg exposure, retentions were measured in whole body, organs, and fetuses. Results (expressed as the percentage of 203 Hg dose) showed that all retention values among treated animals were lower than in the control group. Significantly higher reduction of whole body gut, liver, kidney, and brain retentions in Mi-ADMS (to 2-5% of control values) than in DMSA-treated groups (to 37-80% of control values) was found. 203 Hg retention in uterus, fetuses, and placentae were reduced to 7-8% in Mi-ADMS and to 41-56% of control value in DMSA group. The major routes of 203 Hg excretion after DMSA treatment was urine, whereas fecal excretion was the same as that of controls. After Mi-ADMS treatment, both urinary and fecal 203 Hg excretions were ∼2-3 times higher than the control values resulting in the lowest body retention.